An eagerly awaited result presented by Tony Mok CUHK Medicine on CheckMate 722 in #esmoasia22 . A negative study and even if the sample size is large enough to meet statistical significance, the 2 week PFS difference is not impressive.
Congratulations to Dr Karine Azar from CHU Notre Dame des Secours presenting a poster during poster session at #ESMOAsia22
I am honored to present the result of the Asian sup-group of RATIONALE-306 study, which compared chemotherapy vs. chemo plus tislelizumab for 1st line chemo of ESCC. #ESMOAsia22 #Esophageal
Poster with updated results from ADAURA study A/Prof Tom John also a succinct mini oral presentation yesterday by Tom. ILD rate still around 3% and would need some soul searching on how this would take on for patients as they embark on an adjuvant 3 year drug journey. #ESMOAsia22
Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1 . Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22
Congratulations, #ESMOAsia22 for a successful F2F conference! Glad to have met a lot of colleagues and learned from the experts in the field of Oncology. 😊
Nice lecture in the morning by #johnhannen & #laviniaspain on irAE with interesting data on IO rechallenge and toci prophylaxis and Rashid Lui 雷諾信 discussion on ir-colitis #ESMOAsia22
Country and gender (non-)diversity in oncology clinical trials at #ASCO22
A study by #GLOWgroup
Poster 432P @ #ESMOAsia22
AmyGDavies Joanna Young Maite Bourlon Hans Prenen Prof. Eva Segelov OncoAlert
Our fearless leader Dr Deme Karikios representing Medical Oncology Group of Australia at #ESMOAsia22 #🇦🇺
#ESMOAsia22 Opening cerimony! Happy to be here in person this year! Important meeting to discuss the disparities in cancer patient care and for networking!
Thanks for the face to face meeting ESMO. Great to meet Stephen V Liu, MD in person today. #ESMOAsia22 Stephen V Liu, MD
